Standard BioTools
Open
$0.89
Prev. Close
$0.89
High
$0.89
Low
$0.88
Market Snapshot
$346.27M
4.4
-0.54
$136.84M
387
Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. The company is headquartered in Boston, Massachusetts and currently employs 385 full-time employees. The company went IPO on 2011-02-10. The firm develops, manufactures and sells a diversified range of instrumentation, consumables, and services. The firm's Genomics business includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. Its Biomark X9 system for high-throughput genomics delivers scalability for qPCR applications. Designed for researchers who require robust multiplexing capabilities, the Biomark X9 system enables the simultaneous analysis of thousands of reactions in a single run. By leveraging advanced microfluidics technology, it reduces reagent consumption while increasing throughput, making it a solution for large-scale genomic studies, clinical research, and biomarker discovery. The Biomark X9 system integrates with data analysis tools, accelerating workflows and providing comprehensive insights.
Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. The company is headquartered in Boston, Massachusetts and currently employs 385 full-time employees. The company went IPO on 2011-02-10. The firm develops, manufactures and sells a diversified range of instrumentation, consumables, and services. The firm's Genomics business includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. Its Biomark X9 system for high-throughput genomics delivers scalability for qPCR applications. Designed for researchers who require robust multiplexing capabilities, the Biomark X9 system enables the simultaneous analysis of thousands of reactions in a single run. By leveraging advanced microfluidics technology, it reduces reagent consumption while increasing throughput, making it a solution for large-scale genomic studies, clinical research, and biomarker discovery. The Biomark X9 system integrates with data analysis tools, accelerating workflows and providing comprehensive insights.
Recently from Cashu
Standard BioTools: Leading Innovation and Growth in the Biotechnology Sector
Innovative Growth in the Biotechnology Sector: The Standard BioTools Perspective As the biotechnology industry continues to evolve, companies within this sector strive for innovation and growth amidst…
Standard BioTools Set for Key Earnings Report Amidst Analyst Expectations and Market Insights
Standard BioTools Prepares for Quarterly Earnings Report: Analyst Insights and Expectations Standard BioTools, a prominent player in bioscience tools, gears up for the release of its quarterly earning…
Standard BioTools Prepares for Key Quarterly Earnings Report on February 24, 2026
Earnings Preparation: Standard BioTools Gears Up for Quarterly Report Standard BioTools is poised to release its quarterly earnings report on February 24, 2026, a key event that will provide a compreh…
Standard BioTools Prepares for Key Earnings Report Amidst Competitive Biotechnology Landscape
Approaching Earnings Release: Insight into Standard BioTools' Future Directions Standard BioTools prepares to disclose its quarterly earnings on February 24, 2026, a significant event for stakeholders…